205 related articles for article (PubMed ID: 15785748)
1. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy.
Santin AD; Zhan F; Cane' S; Bellone S; Palmieri M; Thomas M; Burnett A; Roman JJ; Cannon MJ; Shaughnessy J; Pecorelli S
Br J Cancer; 2005 Apr; 92(8):1561-73. PubMed ID: 15785748
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE).
Santin AD; Bellone S; Marizzoni M; Palmieri M; Siegel ER; McKenney JK; Hennings L; Comper F; Bandiera E; Pecorelli S
Cancer; 2007 Apr; 109(7):1312-22. PubMed ID: 17326053
[TBL] [Abstract][Full Text] [Related]
3. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S
Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230
[TBL] [Abstract][Full Text] [Related]
4. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling.
Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Gokden M; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S
Br J Cancer; 2004 May; 90(9):1814-24. PubMed ID: 15208622
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.
Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Bignotti E; Anfossi S; Gokden M; Dunn D; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S
Int J Cancer; 2004 Oct; 112(1):14-25. PubMed ID: 15305371
[TBL] [Abstract][Full Text] [Related]
6. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization.
Odicino FE; Bignotti E; Rossi E; Pasinetti B; Tassi RA; Donzelli C; Falchetti M; Fontana P; Grigolato PG; Pecorelli S
Int J Gynecol Cancer; 2008; 18(1):14-21. PubMed ID: 17451461
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of HER-2/neu in uterine serous papillary cancer.
Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
[TBL] [Abstract][Full Text] [Related]
8. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
9. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer.
Bellone S; Watts K; Cane' S; Palmieri M; Cannon MJ; Burnett A; Roman JJ; Pecorelli S; Santin AD
Gynecol Oncol; 2005 Jul; 98(1):92-8. PubMed ID: 15904949
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).
El-Sahwi K; Bellone S; Cocco E; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Mol Cancer Ther; 2010 Jan; 9(1):57-66. PubMed ID: 20053761
[TBL] [Abstract][Full Text] [Related]
11. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
[TBL] [Abstract][Full Text] [Related]
12. Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer.
Cocco E; Bellone S; El-Sahwi K; Cargnelutti M; Casagrande F; Buza N; Tavassoli FA; Siegel ER; Visintin I; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Br J Cancer; 2009 Jul; 101(2):335-41. PubMed ID: 19536090
[TBL] [Abstract][Full Text] [Related]
13. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma.
Cocco E; Hu Z; Richter CE; Bellone S; Casagrande F; Bellone M; Todeschini P; Krikun G; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Buza N; Pecorelli S; Lockwood CJ; Santin AD
Br J Cancer; 2010 Sep; 103(6):812-9. PubMed ID: 20700124
[TBL] [Abstract][Full Text] [Related]
14. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
[TBL] [Abstract][Full Text] [Related]
15. Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody.
Bellone M; Cocco E; Varughese J; Bellone S; Todeschini P; El-Sahwi K; Carrara L; Guzzo F; Schwartz PE; Rutherford TJ; Pecorelli S; Marshall DJ; Santin AD
Int J Gynecol Cancer; 2011 Aug; 21(6):1084-90. PubMed ID: 21633302
[TBL] [Abstract][Full Text] [Related]
16. Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer.
Konecny GE; Agarwal R; Keeney GA; Winterhoff B; Jones MB; Mariani A; Riehle D; Neuper C; Dowdy SC; Wang HJ; Morin PJ; Podratz KC
Gynecol Oncol; 2008 May; 109(2):263-9. PubMed ID: 18313739
[TBL] [Abstract][Full Text] [Related]
17. Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature.
Hornreich G; Beller U; Lavie O; Renbaum P; Cohen Y; Levy-Lahad E
Gynecol Oncol; 1999 Nov; 75(2):300-4. PubMed ID: 10525392
[TBL] [Abstract][Full Text] [Related]
18. GLUT1 and p63 expression in endometrial intraepithelial and uterine serous papillary carcinoma.
Idrees MT; Schlosshauer P; Li G; Burstein DE
Histopathology; 2006 Jul; 49(1):75-81. PubMed ID: 16842248
[TBL] [Abstract][Full Text] [Related]
19. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
Maxwell GL; Chandramouli GV; Dainty L; Litzi TJ; Berchuck A; Barrett JC; Risinger JI
Clin Cancer Res; 2005 Jun; 11(11):4056-66. PubMed ID: 15930340
[TBL] [Abstract][Full Text] [Related]
20. Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer.
Cocco E; Casagrande F; Bellone S; Richter CE; Bellone M; Todeschini P; Holmberg JC; Fu HH; Montagna MK; Mor G; Schwartz PE; Arin-Silasi D; Azoudi M; Rutherford TJ; Abu-Khalaf M; Pecorelli S; Santin AD
BMC Cancer; 2010 Jul; 10():349. PubMed ID: 20598131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]